The short version of incretin fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-06 and is reviewed periodically as new material appears.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Racecadotril is rapidly absorbed after oral administration and reaches Cmax within 60 minutes. Food delays Cmax by 60 to 90 minutes but does not affect the overall bioavailability. Racecadotril is rapidly and effectively metabolized to the moderately active S-acetylthiorphan the main active metabolite thiorphan, of which 90% are bound to blood plasma proteins. In therapeutic doses, racecadotril does not pass the blood–brain barrier. Inhibition of enkephalinases starts 30 minutes after administration, reaches its maximum (75–90% inhibition with a therapeutic dose) two hours after administration, and lasts for eight hours. The elimination half-life, measured from enkephalinase inhibition, is three hours. Thiorphan is further metabolized to inactive metabolites such as the methyl thioether and the methyl sulfoxide. Both active and inactive metabolites are excreted, mostly via the kidney (81.4%), and to a lesser extent via the feces (8%).
== History == Willis Carrier, a mechanical engineer working for Buffalo Forge, is credited with inventing modern air conditioning in July 1902. In 1908, the Carrier Air Conditioner Company of America was created as a subsidiary of the Buffalo Forge Company, with Willis Carrier as its vice president. With the onset of World War I in late 1914, the Buffalo Forge Company, where Carrier had been employed for 12 years, decided to confine its activities entirely to manufacturing. The result was that in 1915, Carrier and six other engineers pooled $32,600 to form the Carrier Engineering Corporation. They purchased their first factory in 1920, in Newark, New Jersey. The very next year, Carrier solved a problem that had vexed the Islington Studios (owned by Famous Players–Lasky and then Paramount Pictures) in London -- thick fog coming into the stage set and suspending filming. A pressurized system that cooled air at a rate of "3,500,000 gallons per hour" and then delivered the dehumidified air at the temperature set by a thermostat, kept the interior air clear and camera-ready. In 1955, Carrier merged with Affiliated Gas Equipment, Inc., which owned the Bryant Heater Co., Day & Night Water Heater Co., and Payne Furnace & Supply Co. Carrier Corporation was acquired by United Technologies Corporation (UTC) in July 1979. Prior to the acquisition by UTC, Carrier Corporation was known as the Carrier Air Conditioning Company. International Comfort Products (ICP), headquartered in Lewisburg, Tennessee, was acquired by Carrier in 1999.
The builders of the empire planned and built impressive structures in their city centers, including canals, fountains, drainage systems and expansive irrigation. Inca's infrastructure and water supply system have been hailed as “the pinnacle of the architectural and engineering works of the Inca civilization”. Major Inca centers were chosen by experts who decided the site, its apportionment, and the basic layout of the city. In many cities we see great hydraulic engineering marvels. For example, in the city of Tipon, 3 irrigation canals diverted water from Rio Pukara to Tipon which is about 1.35 km north for Tipon's terraces. Tipon also had natural springs that they built fountains for that supplied noble residents with water for non agricultural purposes.
Since its half-life of 5.5 to 26 hours is quite long, consciousness would take a long time to return. In veterinary medicine, sodium thiopental is used to induce anesthesia in animals. Since it is redistributed to fat, certain lean breeds of dogs such as sighthounds have prolonged recoveries from sodium thiopental due to their lack of body fat. Conversely, obese animals recover rapidly, but it takes much longer for the drug to be entirely removed (metabolized) from their bodies. Sodium thiopental is always administered intravenously, as it can be fairly irritating to tissue and is a vesicant; severe tissue necrosis and sloughing can occur if it is injected incorrectly into the tissue around a vein.
Sources: en.wikipedia.org
Avoiding the use of bisphosphonates is not a viable preventive strategy on a general-population basis because the medications are beneficial in the treatment and prevention of osteoporosis (including prevention of bony fractures) and treatment of bone cancers. Current recommendations are for a 2-month drug holiday prior to dental surgery for those who are at risk (intravenous drug therapy, greater than 4 years of by-mouth drug therapy, other factors that increase risk such as steroid therapy). It usually develops after dental treatments involving exposure of bone or trauma, but may arise spontaneously. Patients who develop MRONJ may experience prolonged healing, pain, swelling, infection and exposed bone after dental procedures, though some patients may have no signs/symptoms.
== Focus of Transfusion Practitioners == It is a specialist role focusing on patient safety through best practice and appropriate use of blood and blood products. Much of the work of TPS centres on aligning practices with local, national, or international standards and guidelines. There are many activities that comprise the TP role and some or all of these may be within TPs position (job) descriptions depending on the area they work, and the strategic direction of the organisation they work in. TP activities aim to increase awareness and knowledge to improve clinical decision making and enhance practice. Transfusion practice require a multidisciplinary approach and TPs are seen as the link between different health professionals and departments, such as clinical and laboratory colleagues, as well as patients. To comply with governance, regulations and mandatory standards many organisations have established Blood Management Committees or Hospital Transfusion Committees. A TPs responsibilities include risk management, surveillance of appropriate use, coordinating patient blood management strategies, blood waste minimisation and investigation and analysis of events. These committees ideally include multidisciplinary membership, and provide support, guidance, and endorsement of the TP activities. The TP plays an essential role in supporting the work of the committee. Transfusion Practitioners improve transfusion practice by promoting safe transfusion practice in a variety of ways. Activities of the TP may include:
== Dalgona == Dalgona is a traditional Korean hard candy made with sugar and baking soda. But for Dalgona coffee, instead of putting hard formation candy into the coffee, make a whipped cream foam with Americano and sugar. Then put the Dalgona cream on top of the milk of your choice. Dalgona coffee was newly invented during the COVID-19 pandemic. The reason Dalgona coffee got viral during that period was due to the pandemic; people were in a situation where they had to stay home for safety. The regulation of the pandemic was when the COVID-19 test results came out to be positive, people had to quarantine for 14 days. With this background situation, people kept searching for things that they could stay active and productive during the time they stay home. The process of making Dalgona coffee was perfect for people. To make Dalgona whip cream, at least 400 times or more stirring process is needed. It's hard to make, but it was a creative and innovative taste of coffee at that time because people could make 'coffee shop' coffee at home. People started to post themselves making Dalgona coffee and this became some sort of trend 'Dalgona coffee challenge' and it spread through social media such as Google, Instagram, TikTok and YouTube. It went viral not only in Korea but also it went widespread all over the world included not only the Asia but also Central and South America. Even after the pandemic ended, lots of coffee shops in Korea launched Dalgona coffee as one of the new menu items. One of the popular coffee chain, Ediya coffee launched 'Dalgona latte' in May 2020.
== Structure == The NDUFB2 gene, located on the q arm of chromosome 7 in position 34, is 9,966 base pairs long and is composed of 4 exons. The NDUFB2 protein weighs 12 kDa and is composed of 105 amino acids. NDUFB2 is a subunit of the enzyme NADH dehydrogenase (ubiquinone), the largest of the respiratory complexes. The structure is L-shaped with a long, hydrophobic transmembrane domain and a hydrophilic domain for the peripheral arm that includes all the known redox centers and the NADH binding site. NDUFB3 is one of about 31 hydrophobic subunits that form the transmembrane region of Complex I. It has been noted that the N-terminal hydrophobic domain has the potential to be folded into an alpha helix spanning the inner mitochondrial membrane with a C-terminal hydrophilic domain interacting with globular subunits of Complex I. The highly conserved two-domain structure suggests that this feature is critical for the protein function and that the hydrophobic domain acts as an anchor for the NADH dehydrogenase (ubiquinone) complex at the inner mitochondrial membrane. Hydropathy analysis revealed that this subunit and 4 other subunits have an overall hydrophilic pattern, even though they are found within the hydrophobic protein (HP) fraction of complex I.
Following the initial sequential resonance assignment, it is usually possible to extend the assignment from the Cα and Cβ to the rest of the sidechain using experiments such as HCCH-TOCSY, which is basically a TOCSY experiment resolved in an additional carbon dimension.
Sources: en.wikipedia.org
Machine vision systems often require bright and homogeneous illumination, so features of interest are easier to process. LEDs are often used. Barcode scanners are the most common example of machine vision applications, and many of those scanners use red LEDs instead of lasers. Optical computer mice use LEDs as a light source for the miniature camera within the mouse. LEDs are useful for machine vision because they provide a compact, reliable source of light. LED lamps can be turned on and off to suit the needs of the vision system, and the shape of the beam produced can be tailored to match the system's requirements.
== A == abietadiene hydroxylase - acido-1 RNA motif -acrylamide gels - act 1 adaptor protein - actino-ugpB RNA motif - actinomyces-1 RNA motif - adenine - adenosine deaminase deficiency - adenovirus - adenylyl-(glutamate—ammonia ligase) hydrolase - agarose gel electrophoresis - agarose gel - akaryocyte - Alagille syndrome - alkaline lysis - allele - amino acids - amino terminus - amp resistance - amplification - amplicon - anchor sequence - animal model - anneal - anti-sense strand - antibiotic resistance - antibody - antisense - antisense strand - AP-1 site - apo-beta-carotenoid-14',13'-dioxygenase - apoptosis - apovitellenin-1 - archease - arenicin - ArgJ protein family - ascorbate 2,3-dioxygenase - assembled epitope - ataxia-telangiectasia - ATG or AUG - ATP cone - Atrial septal defect 1 - autoimmune lymphoproliferative syndrome - autoradiography - autosomal dominant - autosome - avidin -
Next come the 4p orbitals, completing the row, which are filled progressively by gallium ([Ar] 3d10 4s2 4p1) through krypton ([Ar] 3d10 4s2 4p6), in a manner analogous to the previous p-block elements. From gallium onwards, the 3d orbitals form part of the electronic core, and no longer participate in chemistry. The s- and p-block elements, which fill their outer shells, are called main-group elements; the d-block elements (coloured blue below), which fill an inner shell, are called transition elements (or transition metals, since they are all metals). The next 18 elements fill the 5s orbitals (rubidium and strontium), then 4d (yttrium through cadmium, again with a few anomalies along the way), and then 5p (indium through xenon). Again, from indium onward the 4d orbitals are in the core. Hence the fifth row has the same structure as the fourth.
In 1972, eight remarkably preserved mummies were discovered at an abandoned Inuit settlement called Qilakitsoq, in Greenland. The "Greenland Mummies" consisted of a six-month-old baby, a four-year-old boy, and six women of various ages, who died around 500 years ago. Their bodies were naturally mummified by the sub-zero temperatures and dry winds in the cave in which they were found.
=== Action on the cell === After insulin enters the bloodstream, it binds to a membrane-spanning receptor tyrosine kinase (RTK). This glycoprotein is embedded in the cellular membrane and has an extracellular receptor domain, made up of two α-subunits, and an intracellular catalytic domain made up of two β-subunits. The α-subunits act as insulin receptors and the insulin molecule acts as a ligand. Together, they form a receptor-ligand complex. Binding of insulin to the α-subunit results in a conformational change of the protein, which activates tyrosine kinase domains on each β-subunit. The tyrosine kinase activity causes an autophosphorylation of several tyrosine residues in the β-subunit. The phosphorylation of 3 residues of tyrosine is necessary for the amplification of the kinase activity. This autophosphorylation triggers the activation of the docking proteins, in this case IRS (1-4) on which phosphatidylinositol-3-Kinase (PI-3K) can be attached or GRB2 where the ras guanine nucleotide exchange factor (GEF) (also known as SOS) can be attached. PI-3K causes the phosphorylation of PIP2 to PIP3. This phospholipid acts as a docking site for PDPK1 and AKT2, which is then phosphorylated by the latter and PK2 to be activated. This leads to crucial metabolic functions such as synthesis of lipids, proteins, and glycogen. It also leads to cell survival and cell proliferation. Most importantly, the PI-3K pathway is responsible for the distribution of glucose for important cell functions.
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.